Raloxifene (hydrochloride)

Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1].

Product Specifications

CAS Number

[82640-04-8]

Product Name Alternative

Keoxifene (hydrochloride) ; LY156758; LY139481 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Estrogen Receptor/ERR

Type

Natural Products

Related Pathways

Autophagy; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/raloxifene-hydrochloride.html

Purity

99.91

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(C2=CC=C(O)C=C2)SC3=CC(O)=CC=C31)C4=CC=C(OCCN5CCCCC5)C=C4.Cl

Molecular Formula

C28H28ClNO4S

Molecular Weight

510.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Yang, N.N., et al., Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology, 1996. 137 (5) : p. 2075-84.|[2]Obach, R.S., Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos, 2004. 32 (1) : p. 89-97.|[3]Sato, M., M.K. Rippy, and H.U. Bryant, Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J, 1996. 10 (8) : p. 905-12.|[4]Black, L.J., et al., Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest, 1994. 93 (1) : p. 63-9.|[5]Shibata MA, et al. Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer.BMC Cancer. 2010 Oct 19;10:566.